[1] WHO. Update of recommendations on first- and second-line antiretroviral regimens. Geneva: WHO, 2019.
[2] You JZ, Wang HR, Huang XJ, et al. Therapy-emergent drug resistance to integrase strand transfer inhibitors in HIV-1 patients: a subgroup meta-analysis of clinical trials. PLoS One, 2016; 11, e0160087. doi:  10.1371/journal.pone.0160087
[3] Zuo LL, Liu K, Liu HL, et al. Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001−2017). E Clin Med, 2020; 18, 100238. doi:  10.1016/j.eclinm.2019.100238
[4] The Central People's Government of the People's Republic of China. Anhui province basic medical insurance drug list (implemented from January 1, 2020). http://www.audit.gov.cn/en/n751/index.html. [2020]. (In Chinese)
[5] Hurt CB, Sebastian J, Hicks CB, et al. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009−2012. Clin Infect Dis, 2014; 58, 423−31. doi:  10.1093/cid/cit697
[6] Liu LF, Dai LL, Yao J, et al. Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naive individuals in a tertiary care hospital in Beijing, China. AIDS, 2019; 33, 1945−7. doi:  10.1097/QAD.0000000000002282
[7] Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med, 2019; 27, 111−21.
[8] Hassounah SA, Alikhani A, Oliveira M, et al. Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1. Antimicrob Agents Chemother, 2017; 61, e01695−17.
[9] Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother, 2011; 55, 813−21. doi:  10.1128/AAC.01209-10
[10] WHO. Guidelines on the public health response to pretreatment HIV drug resistance: July 2017. Geneva: WHO, 2017.
[11] Hurt CB. Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir Ther, 2011; 16, 137−40. doi:  10.3851/IMP1750